.webp)
O Probiótico Nº 1 do mundo1 que Restabelece e Equilibra a Flora intestinal*2
.svg)
.svg)
-(1).webp/jcr:content/pdp_dk_1_1x%20(2)%20(1).webp)
Enterogermina® Plus
Resistente a antibióticos7
Fácil de Tomar, apenas 1 flaconete por dia
Seguro a partir do primeiro dia de vida
Enterogermina® Adulto Max
Resistente a antibióticos7
Exclusivo para Adultos
Formato inovador: dissolve direto na boca
Conte com Enterogermina no caso de desequilíbrio intestinal associado a:
.webp)
.webp)
REFERÊNCIAS
*Uma flora intestinal equilibrada promove um ambiente desfavorável para bactérias patogênicas, promovendo a saúde intestinal.
- Nicholas Hall’s glocal chc databas, DB6 MAT Q3 2023.
- Lopetuso L et al 2016; Paixão e Castro, 2016.
- Ghelardi, E., et al., Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation. J Appl Microbiol, 2015. 119(2): p. 552-9.
- Vecchione, A., et al., Compositional Quality and Potential Gastrointestinal Behavior of Probiotic Products Commercialized in Italy. Front Med (Lausanne), 2018. 5: p. 59.
- Giua et al (2024). A Prospective Real‑World Study of Bacillus clausii Evaluating Use, Treatment Habits and Patient Satisfaction in Italian Community Pharmacies: The PEGASO Study. Drugs - Real World Outcomes (2024) 11:137–147.
- Paparo L et al. Protective action of Bacillus clausii probiotic strains in an in vitro model of Rotavirus infection. Sci Rep. 2020;10:12636.
- Senesi, S., et al., Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy. Appl Environ Microbiol, 2001. 67(2): p. 834-9.
- Tarasiuk A & Fichna J. J Expert Rev Clin Pharmacol. 2019;12:921-30.
- Leeming ER, et al. Nutrients. 2019;11(12):2862.
- Danis R & Wawruch M. Cent Eur J Public Health. 2022;30:20–25
- Weiss GA & Hennet T. Cell Mol Life Sci. 2017;74:2959-2977
- Danis R & Wawruch M. Cent Eur J Public Health. 2022;30:20–25
- Gulas E, et al. Psychiatr Pol. 2018;52:1023-1039.
- Lahiri K et al. Bacillus clausii As An Adjuvant Therapy In Acute Childhood Diarrhoea. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 2015;14:74-76.
- Giua et al (2024). A Prospective Real‑World Study of Bacillus clausii Evaluating Use, Treatment Habits and Patient Satisfaction in Italian Community Pharmacies: The PEGASO Study. Drugs - Real World Outcomes (2024) 11:137–147.
- Ghelardi et al (2015). Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation. Journal of Applied Microbiology 119, 552-559.
- Castro et al (2019). Bacillus clausii as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE). Tropical Diseases, Travel Medicine and Vaccines 5:14.
%20(7).webp)
.webp)
